Geron sys Patent Office rejected challenge to ViaCyte Patent

Geron Says Patent Office Rejected Challenge to ViaCyte Patent

Geron Corp. (GERN), the biotech company that last year abandoned its stem-cell clinical trials, said the U.S. Patent andTrademark Office turned away its challenge to a stem cell-related patent held by ViaCyte Inc., a San Diego-based competitor.
According to a Geron regulatory filing, the patent office’s Board of Patent appeals and Interferences rejected arguments against claims in ViaCyte’s patent 7,510,876. The board also said that some of the claims in a Geron patent application were unpatentable.
The technology covered by the disputed application is part of its stem cell intellectual property portfolio the Menlo Park, California-based company is seeking to divest, Geron said.
In November 2011 Geron said in a statement that it would discontinue its clinical trials of its stem cell-related therapies to focus on oncology drugs.
Geron is the company that funded the University of Wisconsin research that first isolated stem cells from human embryos in 1998.
In July 2011 the company said it had won clearance from the U.S. Food and Drug Administration to test a therapy derived from those cells. Geron ended those trials because of research costs and regulatory complexities

Geron is trying to sell it's stem cell property, this will made it much harder and worth much less.
It's all going to come down to Dec 2012 the 4 Phase 2 trial results. If good I'm rich, if fair to poor I'll be working tell I drop dead.

Good luck in this rigged casino,